0001714899-26-000064
SEC filingDenali's Q1 2026 operating loss improved to $137.4M, driven by lower R&D costs, while net cash used in operations remained flat at $131.2M.
Denali's operating loss improved to $137.4 million in Q1 2026 from $145.6 million in Q1 2025, a 5.6% improvement. This was primarily driven by lower research and development expenses, partially offset by higher general and administrative costs associated with the launch of AVLAYAH. The net loss narrowed to $128.4 million from $133.0 million, and diluted EPS improved to $(0.69) from $(0.78).
Denali continues to advance its pipeline, with product candidates in later stages of clinical development generally incurring higher costs due to larger and longer trials. The company plans to use both its SLC facility and third-party contract manufacturers for preclinical and clinical materials. The strategic focus remains on launching initial products targeting rare lysosomal storage diseases as a foundation for expansion into common neurodegenerative conditions.
Denali expects general and administrative expenses to increase as it supports growing operations and commercialization activities. The company may need additional funds to meet operational needs if operating plans change. Prior and expected future losses will continue to adversely affect stockholders' equity and working capital. Cost-sharing arrangements with collaboration partners, such as Biogen and Takeda, may impact research and development expenses.